Recombinant CCR4 (Mogamulizumab Biosimilar) antibody

Catalog No. ABIN7795114

The Humanized Monoclonal anti-CCR4 (Mogamulizumab Biosimilar) antibody (ABIN7795114) specifically detects CCR4 (Mogamulizumab Biosimilar) in FACS and in vivo. The antibody is reactive with Human samples.

Quick Overview for Recombinant CCR4 (Mogamulizumab Biosimilar) antibody (ABIN7795114)

Target: CCR4 (Mogamulizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CCR4 (Mogamulizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CCR4 (Mogamulizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Mogamulizumab Biosimilar, CCR4 Monoclonal Antibody

Characteristics: Mogamulizumab Biosimilar uses the same protein sequences as the therapeutic antibody mogamulizumab. Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous, these cancers typically affect the skin, causing various types of skin lesions. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Mogamulizumab selectively binds to and inhibits the activity of CCR4, which may block CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, as well as chemokine-mediated angiogenesis. Additionally, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and certain types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells. In addition to directly targeting malignant T cells expressing CCR4, mogamulizumab depletes Treg cells, an important therapeutic target in many human cancers because of their role in suppressing host antitumor immunity.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CCR4

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CCR4 (Mogamulizumab Biosimilar)

Target: CCR4 (Mogamulizumab Biosimilar)

Alternative Name: Mogamulizumab Biosimilar

Target Type: Biosimilar